TIDMTRX
RNS Number : 6758N
Tissue Regenix Group PLC
21 May 2020
THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES
NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR
ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE
FOR, ANY SECURITIES OF TISSUE REGENIX GROUP PLC.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO
ANY PERSON LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS
UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT.
THIS ANNOUNCEMENT AMOUNTS TO A FINANCIAL PROMOTION FOR THE
PURPOSES OF SECTION 21 OF THE FINANCIAL SERVICES AND MARKETS ACT
2000 ("FSMA") AND HAS BEEN APPROVED BY PRIMARYBID LIMITED WHICH IS
AUTHORISED AND REGULATED BY THE FINANCIAL CONDUCT AUTHORITY (FRN
779021).
21 May 2020
Tissue Regenix Group plc
("Tissue Regenix", the "Group" or the "Company") ( AIM : TRX
)
PrimaryBid.com Offer
Tissue Regenix Group Plc ( AIM : TRX ), a leading regenerative
medicine company, is pleased to announce, a conditional offer for
subscription via PrimaryBid (the "PrimaryBid Offer") of new
ordinary shares ("New Ordinary Shares") at an issue price of 0.25
pence per New Ordinary Share (the "Issue Price"), being a discount
of 76 per cent to the closing mid-price on 20 May 2020. The Company
is also conducting a placing of new Ordinary Shares at the Issue
Price by way of an accelerated bookbuild process by Stifel Nicolaus
Europe Limited and Allenby Capital Limited, acting as sub-placing
agent, (the "Placing") as announced on 21 May 2020.
The PrimaryBid Offer and the Placing are conditional on the new
Ordinary Shares to be issued pursuant to the PrimaryBid Offer and
the Placing being admitted to trading on London Stock Exchange
("Admission"). Admission is expected to be take place at 8.00 a.m.
on or around 10 June 2020, and that dealings in the New Ordinary
Shares will commence at that time, and in any event no later than
30 June 2020. The PrimaryBid Offer will not be completed without
the Placing also being completed and is conditional on, inter alia,
the passing of the Placing Resolutions to be proposed at a General
Meeting expected to be held at the Company's offices of Squire
Patton Boggs (UK) LLP, 6 Wellington Place, Leeds at 12 pm on 9 June
2020, as well as the successful capital reorganisation of the
Company.
The Company will use the funds raised to fund the Group's
manufacturing capacity expansion programme in the US, commencing
immediately, and for general working capital purposes.
For more information about the Company, please visit the Issuer
Services Page, a service provided by London Stock Exchange, at
https://profile.lsegissuerservices.com/TissueRegenixGroup/overview
.
PrimaryBid Offer
The Company values its retail investor base and is therefore
pleased to provide private and other investors the opportunity to
participate in the PrimaryBid Offer by applying exclusively through
the www.PrimaryBid.com platform and the PrimaryBid mobile app
available on the Apple App Store and Google Play. PrimaryBid does
not charge investors any commission for this service.
The PrimaryBid Offer, via the PrimaryBid.com platform, will be
open to individual and institutional investors from 4.35 p.m. on
21(st) May 2020 to 9 p.m. on 21(st) May 2020 . The PrimaryBid Offer
may close early if it is oversubscribed.
Subscriptions under the PrimaryBid Offer will be considered by
the Company on a "first come, first served" basis, subject to
conditions which are available to view on PrimaryBid.com.
The Company in consultation with PrimaryBid reserves the right
to scale back any order at its discretion. The Company and
PrimaryBid reserve the right to reject any application for
subscription under the Offer without giving any reason for such
rejection.
No commission is charged to investors on applications to
participate in the PrimaryBid Offer made through PrimaryBid. It is
vital to note that once an application for New Ordinary Shares has
been made and accepted via PrimaryBid, an application cannot be
withdrawn.
For further information on PrimaryBid.com or the procedure for
applications under the PrimaryBid Offer, visit www.PrimaryBid.com
or call PrimaryBid.com on +44 20 3026 4750.
The New Ordinary Shares will be issued free of all liens,
charges and encumbrances and will, when issued and fully paid, rank
pari passu in all respects with the Company's existing Ordinary
Shares.
+ 44 (0) 330 430
Tissue Regenix Group plc 3073 /
Caitlin Pearson, Head of Communications + 44 (0) 7920272441
PrimaryBid Limited + 44 (0) 203 026
Kieran D'Silva / James Deal 4750
Stifel Nicolaus Europe Limited + 44 (0) 207 710
Jonathan Senior/Alex Price/Ben Maddison 7600
FTI Consulting
Simon Conway / Victoria Foster Mitchell / Mary + 44 (0) 203 727
Whittow 1000
Details of the Offer
The Company highly values its retail investor base which has
supported the Company alongside institutional investors over
several years. Given the longstanding support of retail
shareholders, the Company believes that it is appropriate to
provide retail and other interested investors the opportunity to
participate in the Offer. The Company is therefore making the Offer
available exclusively through PrimaryBid.com.
The Offer is offered under the exemptions against the need for a
prospectus allowed under the Prospectus Rules. As such, there is no
need for publication of a prospectus pursuant to the Prospectus
Rules, or for approval of the same by the Financial Conduct
Authority in its capacity as the UK Listing Authority. The Offer is
not being made into any Restricted Jurisdiction or any other
jurisdiction where it would be unlawful to do so.
There is a minimum subscription of GBP100 per investor under the
terms of the Offer which is open to existing shareholders and other
investors subscribing via PrimaryBid.com. This allocation will be
filled on a "first come first served" basis.
For further details please refer to the PrimaryBid.com website
at www.PrimaryBid.com . The terms and conditions on which the Offer
is made, including the procedure for application and payment for
New Ordinary Shares, is available to all persons who register with
PrimaryBid.com.
Investors should make their own investigations into the merits
of an investment in the Company. Nothing in this announcement
amounts to a recommendation to invest in the Company or amounts to
investment, taxation or legal advice.
It should be noted that a subscription for New Ordinary Shares
and investment in the Company carries a number of risks. Investors
should consider the risk factors set out on PrimaryBid.com before
making a decision to subscribe for New Ordinary Shares. Investors
should take independent advice from a person experienced in
advising on investment in securities such as the New Ordinary
Shares if they are in any doubt.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com .
END
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEABMATMTITBIM
(END) Dow Jones Newswires
May 21, 2020 11:47 ET (15:47 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2023 to Jul 2024